Human CXCR5(+)PD‐1(+) CD8 T cells in healthy individuals and patients with hematologic malignancies

Immune checkpoint blockade (ICB) has revolutionized cancer therapy, but varying response rates illustrate the need for biomarkers of response. Studies in mice have identified a subset of CD8 T cells that is essential for response to PD‐1 ICB. These CD8 T cells co‐express CXCR5, PD‐1 and Tcf1, and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofland, Tom, Martens, Anne W.J., van Bruggen, Jaco A.C., de Boer, Renate, Schetters, Sjoerd, Remmerswaal, Ester B.M., Bemelman, Frederike J., Levin, Mark‐David, Bins, Adriaan D., Eldering, Eric, Kater, Arnon P., Tonino, Sanne H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Tumor immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984320/
https://www.ncbi.nlm.nih.gov/pubmed/33098668
http://dx.doi.org/10.1002/eji.202048761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984320/
https://www.ncbi.nlm.nih.gov/pubmed/33098668
http://dx.doi.org/10.1002/eji.202048761

Ejemplares similares